Flow Cytometry Leukemia/Lymphoma Antibody Panel Receives Approval
By LabMedica International staff writers Posted on 06 May 2019 |
Image: Normal and abnormal control cells from the ClearLLab 10C kit (Photo courtesy of Beckman Coulter).
A panel of immune-phenotyping flow cytometer reagents that identifies both lymphoid and myeloid cell lines has been granted diagnostic marketing clearance by the [U.S.] Food and Drug Administration to complement its European IVD classification.
The Beckman Coulter (Brea, CA, USA) ClearLLab 10C System offers all components needed: from quality controls, sample preparation and antibody panels to analysis software and training materials. The ClearLLab 10C dry pre-mixed antibody panels rely on DURA Innovations technology, eliminating the need to pipette antibodies, thereby improving efficiency while reducing potential for human error.
The DURA (Dry Unitized Reagent Assays) drying process creates a uniform reagent layer at the bottom of the tubes. The reagents do not require refrigeration, which allows the technician to produce a single batch and store it at room temperature for the duration of the study.
The ClearLLab 10C kit contains four premixed, dry 10-color panels: Lymphoid (B-cells, T-cells), Myeloid (M1, M2). In addition, there are normal and abnormal control cells as a liquid preparation of stabilized human erythrocytes and leukocytes. The kit, which was validated for the use on the Beckman Coulter Navios/Navios EX flow cytometers, uses Kaluza C analysis software for data analysis and reporting.
ClearLLab 10C is supported by a unique resource, the ClearLLab 10C case book. The case book provides 24 diagnostic vignettes giving characteristic findings after flow cytometric analysis, with expert assessment by hematopathologists.
The Beckman Coulter (Brea, CA, USA) ClearLLab 10C System offers all components needed: from quality controls, sample preparation and antibody panels to analysis software and training materials. The ClearLLab 10C dry pre-mixed antibody panels rely on DURA Innovations technology, eliminating the need to pipette antibodies, thereby improving efficiency while reducing potential for human error.
The DURA (Dry Unitized Reagent Assays) drying process creates a uniform reagent layer at the bottom of the tubes. The reagents do not require refrigeration, which allows the technician to produce a single batch and store it at room temperature for the duration of the study.
The ClearLLab 10C kit contains four premixed, dry 10-color panels: Lymphoid (B-cells, T-cells), Myeloid (M1, M2). In addition, there are normal and abnormal control cells as a liquid preparation of stabilized human erythrocytes and leukocytes. The kit, which was validated for the use on the Beckman Coulter Navios/Navios EX flow cytometers, uses Kaluza C analysis software for data analysis and reporting.
ClearLLab 10C is supported by a unique resource, the ClearLLab 10C case book. The case book provides 24 diagnostic vignettes giving characteristic findings after flow cytometric analysis, with expert assessment by hematopathologists.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms